Vaxcyte, Inc. (PCVX)

Vaxcyte's stock has experienced several notable events over the past six months. The company closed a $632.5 million public offering of common stock in February 2026. In November 2025, Q3 2025 earnings were reported with an EPS of -$1.56, missing analysts' estimates. In March 2025, the stock experienced a sell-off after the company presented its first VAX-24 data in infants, which missed expectations on 4 serotypes. Vaxcyte reported advancement of its VAX-31 candidate across adult and infant programs, with dosing begun in the adult OPUS-2 Phase 3 trial and completion of enrollment in the infant Phase 2 dose-finding study. Over the past year, PCVX underperformed both the US Biotechs industry and the broader US Market, with a 52-week trading range between $27.66 and $91.02.

As a clinical-stage company, Vaxcyte currently has no commercial products and therefore generates no product revenue, so direct demand seasonality for its products is not applicable at this time. The diseases Vaxcyte's vaccine candidates target are responsible for significant global morbidity and mortality, particularly in vulnerable populations. Demand for some vaccines, particularly those targeting respiratory illnesses like pneumococcal disease, can exhibit seasonality, with increased vaccination efforts often encouraged during colder months. Once Vaxcyte's products reach commercialization, their demand may be influenced by such seasonal patterns and public health recommendations.

Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines against bacterial diseases. The company engineers broad-spectrum conjugate and novel protein vaccines, including VAX-31, a 31-valent pneumococcal conjugate vaccine candidate advancing to Phase 3 for adults and being evaluated in Phase 2 for infants, designed to prevent invasive pneumococcal disease. VAX-24, a 24-valent PCV candidate, is in a Phase 2 infant study. VAX-A1 is a prophylactic vaccine candidate for Group A Strep infections. VAX-PG is a therapeutic vaccine candidate targeting Porphyromonas gingivalis for periodontal disease, and VAX-GI is a preclinical vaccine candidate to prevent Shigella. Vaxcyte utilizes advanced chemistry and its proprietary XpressCF™ cell-free protein synthesis platform.

Vaxcyte, Inc. is headquartered in San Carlos, California, USA. Its stock (PCVX) is traded on the NASDAQ exchange and is also listed on several European stock exchanges, including Munich, Frankfurt, Stuttgart, Dusseldorf, Hamburg, Berne, and Milan.

Vaxcyte generally holds a positive brand reputation among analysts, with a consensus rating of "Strong Buy" or "Moderate Buy". The company is seen as positioned for strong financial growth, with an increased peak revenue estimate of $6.8 billion by 2040. However, the company's reputation has faced some challenges, including an "underwhelming readout" from the VAX-24 Phase 2 trial in infants and the challenging market environment for vaccine stocks due to increased regulatory scrutiny. Despite these setbacks, the long-term outlook remains compelling for many, with VAX-31 seen as a potential best-in-class PCV.

Vaxcyte, Inc. has significant institutional ownership, with 594 institutional owners holding a total of 165,974,877 shares. Major institutional shareholders include Janus Henderson Group Plc, Fmr Llc, Vanguard Group Inc, RA Capital Management, L.P., BlackRock, Inc., T. Rowe Price Investment Management, Inc., Wellington Management Group Llp, State Street Corp, and D. E. Shaw & Co., Inc. Individual shareholders represent a small fraction of the company's ownership, approximately 0.621%. Founders Grant Pickering and Jeffrey Fairman, PhD, also retain meaningful stakes.